9th Oct 2015 08:07
LONDON (Alliance News) - Avacta Group PLC Friday said its collaborator ProtATonce Ltd demonstrated the first use of Avacta's affimers in assays on the Luminex platform.
Luminex is a technology owned by NASDAQ-listed Luminex Corp, and is used to analyse a small sample volume, such as a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres.
Avacta and ProtATonce in Feburary agreed a collaboration to evaluate affimers, a type of protein that are an engineered alternative to antibodies, with the Luminex platform, and if possible to develop affimer-based assays using the platform.
The results were presented at the Biomarker Summit Europe in Berlin over the last week.
"I am delighted with the collaboration with ProtATonce and the progress that they have made in setting up the assays and evaluating affimers on the Luminex platform. It is critical at this early stage of commercialisation of affimer reagents that they perform well in the hands of collaborators and customers and the number of such examples are building quickly," said Chief Executive Officer Alastair Smith in a statement.
"We're particularly excited by affimers robust performance on the Luminex platform, the market leading multiplex assay technology, as it presents a significant commercial opportunity for Affimer-based multiplexed assays," Smith added.
Shares in Avacta were up 1.0% at 1.41 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta Group